Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2205-2218

  Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; EXTRACELLULAR MATRIX; FIBROBLAST; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENT CELL; LYMPH VESSEL; MOLECULAR MEDICINE; NANOMEDICINE; NEUROFIBROMATOSIS TYPE 2; NONHUMAN; PERFUSION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; NEOPLASMS; PATHOLOGY; VASCULARIZATION;

ANIMALS; HUMANS; MOLECULAR MEDICINE; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84876993950     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.3653     Document Type: Conference Paper

References (173)

1. Vakoc BJ, Lanning RM, Tyrrell JA, et al: Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15:1219-1223, 2009
2. Jain RK: Normalizing tumor vasculature with anti-Angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
3. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
4. Jain RK: Taming vessels to treat cancer. Sci Am 298:56-63, 2008
5. Goel S, Duda DG, Xu L, et al: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121, 2011
6. Jain RK, Wei J, Gullino PM: Pharmacokinetics of methotrexate in solid tumors. J Pharmacokinet Biopharm 7:181-194, 1979
7. Jain RK, Weissbrod JM, Wei J: Mass transport in tumors: Characterization and applications to chemotherapy. Adv Cancer Res 33:251-310, 1980
8. Nugent LJ, Jain RK: Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238-244, 1984
9. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271:58-65, 1994
10. Jain RK, Munn LL, Fukumura D: Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2:266-276, 2002
11. Fukumura D, Duda DG, Munn LL, et al: Tumor microvasculature and microenvironment: Novel insights through intravital imaging in preclinical models. Microcirculation 17:206-225, 2010
12. Brown EB, Campbell RB, Tsuzuki Y, et al: In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 7:864-868, 2001
13. Jain RK: Molecular regulation of vessel maturation. Nat Med 9:685-693, 2003
14. Baluk P, Hashizume H, McDonald DM: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102-111, 2005
15. Nagy JA, Chang SH, Shih SC, et al: Heterogeneity of the tumor vasculature. Semin Thromb Hemost 36:321-331, 2010
16. Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307, 2011
17. Gerlowski LE, Jain RK: Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31:288-305, 1986
18. Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6:559-593, 1987
19. Hobbs SK, Monsky WL, Yuan F, et al: Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95:4607-4612, 1998
20. Yuan F, Leunig M, Huang SK, et al: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356, 1994
21. Eichler AF, Chung E, Kodack DP, et al: The biology of brain metastases-Translation to new therapies. Nat Rev Clin Oncol 8:344-356, 2011
22. Leunig M, Yuan F, Menger MD, et al: Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 52:6553-6560, 1992
23. Yuan F, Salehi HA, Boucher Y, et al: Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54:4564-4568, 1994
24. Fukumura D, Yuan F, Monsky WL, et al: Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 151:679-688, 1997
25. Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al: Pancreas microenvironment promotes VEGF expression and tumor growth: Novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 81:1439-1451, 2001
26. Monsky WL, Mouta Carreira C, Tsuzuki Y, et al: Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: Mammary fat pad versus cranial tumors. Clin Cancer Res 8:1008-1013, 2002
27. Jain RK, Munn LL, Fukumura D: Intravital microsopy of normal and diseased tissues in the mouse, in Goldman RD, Swedlow JR, Specter DL (eds): Live Cell Imaging: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, CSH Press, 2010, pp 475-521
28. Kim P, Chung E, Yamashita H, et al: In vivo wide-Area cellular imaging by side-view endomicroscopy. Nat Methods 7:303-305, 2010
29. Less JR, Posner MC, Skalak TC, et al: Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4:25-33, 1997
30. Hagendoorn J, Tong R, Fukumura D, et al: Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 66:3360-3364, 2006
31. Jain RK: Determinants of tumor blood flow: A review. Cancer Res 48:2641-2658, 1988
32. Endrich B, Reinhold HS, Gross JF, et al: Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 62:387-395, 1979
33. Eskey CJ, Koretsky AP, Domach MM, et al: 2H-nuclear magnetic resonance imaging of tumor blood flow: Spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res 52:6010-6019, 1992
34. Emblem KE, Mouridsen K, Bjornerud A, et al: Vessel architectural imaging identifies cancer patient responders to antiangiogenic therapy. Nat Med (in press)
35. Padera TP, Stoll BR, Tooredman JB, et al: Pathology: Cancer cells compress intratumour vessels. Nature 427:695, 2004
36. Stylianopoulos T, Martin JD, Chauhan VP, et al: Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 109:15101-15108, 2012
37. Netti PA, Roberge S, Boucher Y, et al: Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52:27-46, 1996
38. Baish JW, Netti PA, Jain RK: Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 53:128-141, 1997
39. Jain RK: 1995 Whitaker Lecture: Delivery of molecules, particles, and cells to solid tumors. Ann Biomed Eng 24:457-473, 1996
40. Helmlinger G, Yuan F, Dellian M, et al: Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 3:177-182, 1997
41. Helmlinger G, Sckell A, Dellian M, et al: Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284-1291, 2002
42. Eskey CJ, Koretsky AP, Domach MM, et al: Role of oxygen vs. glucose in energy metabolism in a mammary carcinoma perfused ex vivo: Direct measurement by 31P NMR. Proc Natl Acad Sci U S A 90:2646-2650, 1993
43. Facciabene A, Peng X, Hagemann IS, et al: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475:226-230, 2011
44. Wilson WR, Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393-410, 2011
45. Keith B, Johnson RS, Simon MC: HIF1 and HIF2: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9-22, 2012
46. Semenza GL: Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207-214, 2012
47. Ward PS, Thompson CB: Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308, 2012
48. Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev 13:139-168, 1994
49. Chan N, Bristow RG: "Contextual" synthetic lethality and/or loss of heterozygosity: Tumor hypoxia and modification of DNA repair. Clin Cancer Res 16:4553-4560, 2010
50. Boucher Y, Jain RK: Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. Cancer Res 52:5110-5114, 1992
51. Stohrer M, Boucher Y, Stangassinger M, et al: Oncotic pressure in solid tumors is elevated. Cancer Res 60:4251-4255, 2000
52. Boucher Y, Kirkwood JM, Opacic D, et al: Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51:6691-6694, 1991
53. Roh HD, Boucher Y, Kalnicki S, et al: Interstitial hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor oxygenation and radiation response. Cancer Res 51:6695-6698, 1991
54. Gutmann R, Leunig M, Feyh J, et al: Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size. Cancer Res 52:1993-1995, 1992
55. Less JR, Posner MC, Boucher Y, et al: Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52:6371-6374, 1992
56. Boucher Y, Salehi H, Witwer B, et al: Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 75:829-836, 1997
57. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
58. Padera TP, Kadambi A, di Tomaso E, et al: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883-1886, 2002
59. Willett CG, Boucher Y, Duda DG, et al: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136-8139, 2005
60. Raut CP, Boucher Y, Duda DG, et al: Effects of sorafenib on intra-Tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 7:e26331, 2012
61. Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48:7022-7032, 1988
62. Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors: I. Role of interstitial pressure and convection. Microvasc Res 37:77-104, 1989
63. Boucher Y, Baxter LT, Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 50:4478-4484, 1990
64. Jain RK: Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 81:570-576, 1989
65. Jain RK, Tong RT, Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res 67:2729-2735, 2007
66. Jain RK, Ward-Hartley KA: Tumor blood flow: Characterization, modifications and role in hyperthermia. IEEE Trans Son Ultrason 31:504-526, 1984
67. Zlotecki RA, Boucher Y, Lee I, et al: Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 53: 2466-2468, 1993
68. Lee I, Boucher Y, Demhartner TJ, et al: Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer 69:492-496, 1994
69. Zlotecki RA, Baxter LT, Boucher Y, et al: Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: Network analysis and mechanistic interpretation. Microvasc Res 50:429-443, 1995
70. Sorensen AG, Emblem KE, Polaskova P, et al: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72:402-407, 2012
71. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
72. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
73. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
74. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
75. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010
76. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
77. Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286, 2007
78. Yuan F, Chen Y, Dellian M, et al: Timedependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996
79. Gazit Y, Baish JW, Safabakhsh N, et al: Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation 4:395-402, 1997
80. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95:10820-10825, 1998
81. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al: Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 60:4556-4560, 2000
82. Izumi Y, Xu L, di Tomaso E, et al: Tumour biology: Herceptin acts as an anti-Angiogenic cocktail. Nature 416:279-280, 2002
83. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
84. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
85. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
86. Sorensen AG, Batchelor TT, Zhang WT, et al: A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296-5300, 2009
87. Gerstner ER, Emblem KE, Chi AS, et al: Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma. J Clin Oncol 30:117s, 2012 (suppl; abstr 2009)
88. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009
89. Bergers G, Hanahan D: Modes of resistance to anti-Angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
90. Ferrara N: Pathways mediating VEGFindependent tumor angiogenesis. Cytokine Growth Factor Rev 21:21-26, 2010
91. Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 27:3020-3026, 2009
92. Meyerhardt JA, Ancukiewicz M, Abrams TA, et al: Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One 7:e38231, 2012
93. Tolaney SM, Duda DG, Boucher Y, et al: A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). J Clin Oncol 30:55s, 2012 (suppl; abstr 1026)
94. Zhu AX, Ancukiewicz M, Supko JG, et al: Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study. Clin Cancer Res 19:1557-1566, 2013
95. Duda DG, Willett CG, Ancukiewicz M, et al: Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15:577-583, 2010
96. Lambrechts D, Claes B, Delmar P, et al: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13:724-733, 2012
97. Batchelor TT, Duda DG, di Tomaso E, et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823, 2010
98. Xu L, Duda DG, di Tomaso E, et al: Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69:7905-7910, 2009
99. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 27:3027-3035, 2009
100. Duda DG, Kozin SV, Kirkpatrick ND, et al: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res 17:2074-2080, 2011
101. Kirkpatrick ND, Jain RK: In vivo vessel cooption by glioma cells following chronic antiangiogenic treatment. Cancer Res 70, 2011 (abstr 368)
102. Carmeliet P, Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417-427, 2011
103. Goel S, Fukumura D, Jain RK: Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. Proc Natl Acad Sci U S A 109:E1214, 2012
104. Huang Y, Yuan J, Righi E, et al: Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109:17561-17566, 2012
105. Chauhan VP, Stylianopoulos T, Martin JD, et al: Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7:383-388, 2012
106. Brufsky AM, Hurvitz S, Perez E, et al: RIBBON-2: A randomized, double-blind, placebocontrolled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293, 2011
107. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
108. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
109. Van der Veldt AA, Lubberink M, Bahce I, et al: Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-Angiogenic drugs. Cancer Cell 21:82-91, 2012
110. Yuan F, Dellian M, Fukumura D, et al: Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756, 1995
111. Hamzah J, Jugold M, Kiessling F, et al: Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453:410-414, 2008
112. Huang X, Wong MK, Yi H, et al: Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 62:5727-5735, 2002
113. Li B, Lalani AS, Harding TC, et al: Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 12:6808-6816, 2006
114. Manning EA, Ullman JG, Leatherman JM, et al: A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13: 3951-3959, 2007
115. Shrimali RK, Yu Z, Theoret MR, et al: Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70:6171-6180, 2010
116. Johansson A, Hamzah J, Payne CJ, et al: Tumor-Targeted TNF stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A 109:7841-7846, 2012
117. Huang Y, Goel S, Duda DG, et al: Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res [epub ahead of print on February 25, 2013]
118. Mazzone M, Dettori D, Leite de Oliveira R, et al: Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839-851, 2009
119. Ferrara N: Vascular endothelial growth factor and age-related macular degeneration: From basic science to therapy. Nat Med 16:1107-1111, 2010
120. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367, 2009
121. Jain RK, Finn AV, Kolodgie FD, et al: Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: A potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 4:491-502, 2007
122. Solano JM, Bakri SJ, Pulido JS: Regression of radiation-induced macular edema after systemic bevacizumab. Can J Ophthalmol 42:748-749, 2007
123. Jain RK, Fenton BT: Intratumoral lymphatic vessels: A case of mistaken identity or malfunction? J Natl Cancer Inst 94:417-421, 2002
124. Alitalo K: The lymphatic vasculature in disease. Nat Med 17:1371-1380, 2011
125. Leu AJ, Berk DA, Lymboussaki A, et al: Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res 60:4324-4327, 2000
126. Hoshida T, Isaka N, Hagendoorn J, et al: Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Res 66:8065-8075, 2006
127. Liao S, Cheng G, Conner DA, et al: Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A 108:18784-18789, 2011
128. Leu AJ, Berk DA, Yuan F, et al: Flow velocity in the superficial lymphatic network of the mouse tail. Am J Physiol 267:H1507-H1513, 1994
129. Berk DA, Swartz MA, Leu AJ, et al: Transport in lymphatic capillaries: II. Microscopic velocity measurement with fluorescence photobleaching. Am J Physiol 270:H330-H337, 1996
130. Swartz MA, Berk DA, Jain RK: Transport in lymphatic capillaries: I. Macroscopic measurements using residence time distribution theory. Am J Physiol 270:H324-H329, 1996
131. Hagendoorn J, Padera TP, Kashiwagi S, et al: Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circ Res 95:204-209, 2004
132. Mouta Carreira C, Nasser SM, di Tomaso E, et al: LYVE-1 is not restricted to the lymph vessels: Expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 61:8079-8084, 2001
133. Helmlinger G, Netti PA, Lichtenbeld HC, et al: Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 15:778-783, 1997
134. Griffon-Etienne G, Boucher Y, Brekken C, et al: Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res 59:3776-3782, 1999
135. Hidalgo M, Von Hoff DD: Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 18:4249-4256, 2012
136. Isaka N, Padera TP, Hagendoorn J, et al: Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 64:4400-4404, 2004
137. Fukumura D, Kashiwagi S, Jain RK: The role of nitric oxide in tumour progression. Nat Rev Cancer 6:521-534, 2006
138. Kashiwagi S, Izumi Y, Gohongi T, et al: NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissueengineered blood vessels. J Clin Invest 115:1816-1827, 2005
139. Kashiwagi S, Tsukada K, Xu L, et al: Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 14:255-257, 2008
140. Lahdenranta J, Hagendoorn J, Padera TP, et al: Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 69:2801-2808, 2009
141. Jain RK: Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-3051, 1987
142. McKee TD, Grandi P, Mok W, et al: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66:2509-2513, 2006
143. Diop-Frimpong B, Chauhan VP, Krane S, et al: Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 108: 2909-2914, 2011
144. Netti PA, Berk DA, Swartz MA, et al: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60:2497-2503, 2000
145. Perentes JY, McKee TD, Ley CD, et al: In vivo imaging of extracellular matrix remodeling by tumor-Associated fibroblasts. Nat Methods 6:143-145, 2009
146. Brown E, McKee T, diTomaso E, et al: Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9:796-800, 2003
147. Feng S, Agoulnik IU, Bogatcheva NV, et al: Relaxin promotes prostate cancer progression. Clin Cancer Res 13:1695-1702, 2007
148. Mok W, Boucher Y, Jain RK: Matrix metalloproteinases-1 and-8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 67: 10664-10668, 2007
149. Nakai Y, Isayama H, Ijichi H, et al: Inhibition of renin-Angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103:1644-1648, 2010
150. Wilop S, von Hobe S, Crysandt M, et al: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135:1429-1435, 2009
151. Keizman D, Huang P, Eisenberger MA, et al: Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer 47:1955-1961, 2011
152. Nakai Y, Isayama H, Ijichi H, et al: Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci 103:1489-1492, 2012
153. Liao S, Liu J, Lin P, et al: TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 17:1415-1424, 2011
154. Liu J, Liao S, Diop-Frimpong B, et al: TGF-blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A 109:16618-16623, 2012
155. Tse JM, Cheng G, Tyrrell JA, et al: Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci U S A 109:911-916, 2012
156. Jain RK, Koenig GC, Dellian M, et al: Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev 15:195-204, 1996
157. Hanahan D, Coussens LM: Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309-322, 2012
158. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51, 2010
159. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
160. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6:392-401, 2006
161. Padera TP, Kuo AH, Hoshida T, et al: Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 7:2272-2279, 2008
162. Van Cutsem E, Lambrechts D, Prenen H, et al: Lessons from the adjuvant bevacizumab trial on colon cancer: What next? J Clin Oncol 29:1-4, 2011
163. Langley RR, Fidler IJ: The biology of brain metastasis. Clin Chem 59:180-189, 2013
164. Kodack DP, Chung E, Yamashita H, et al: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-Amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 109: E3119-E3127, 2012
165. Jain RK, Carmeliet P: SnapShot: Tumor angiogenesis. Cell 149:1408-1408.e1, 2012
166. Jain RK, Duda DG, Clark JW, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
167. Zhu AX, Finn RS, Mulcahy M, et al: A phase 2 study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma: Updated results (NCT000627042). Presented at the Fourth Annual Conference of the International Liver Cancer Association, Montreal, Quebec, Canada, September 10-12, 2010 (abstr O-033)
168. Fuchs CS, Tomasek J, Cho JY, et al: REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum-And/or fluoropyrimidine-containing combination therapy. Presented at the 2013 Gastrointestinal Cancers Symposium, San Francisco, CA, January 14-16, 2013 (abstr LBA5)
169. Snuderl M, Batista A, Kirkpatrick ND, et al: Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152:1065-1076, 2013
170. Kerbel RS: Reappraising antiangiogenic therapy for breast cancer. Breast 20:S56-S60, 2011 (suppl 3)
171. Augustin HG, Koh GY, Thurston G, et al: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165-177, 2009
172. Lu KV, Chang JP, Parachoniak CA, et al: VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21-35, 2012
173. Sennino B, McDonald DM: Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12:699-709, 2012